Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
When case Id is present, search is done only for this
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
Don't have an account? Register Here
<h1>Pharma manufacturer wins appeal on Cenvat Credit compliance. Ruling invalidates demand under Rule 6(3)(b).</h1> <h3>M/s. IPCA Laboratories Ltd. Versus C.C.E Indore</h3> M/s. IPCA Laboratories Ltd. Versus C.C.E Indore - 2015 (40) S.T.R. 771 (Tri. - Del.) Issues:1. Whether the appellant complied with the provisions of Rule 6(2) of Cenvat Credit Rules, 2004 regarding maintaining separate accounts for dutiable and exempted final productsRs.2. Whether the provisions of Rule 6(3)(b) apply for payment of an amount equal to 10% of the sale value of the exempted final productRs.3. Whether the retrospective amendment to Rule 6(3) by Finance Act, 2010 impacts the caseRs.Analysis:1. The appellant, a pharmaceutical manufacturer, used 6 common input services for both dutiable and exempted final products. They did not maintain separate accounts for these products as required by Rule 6(2). The Department demanded a significant amount under Rule 6(3)(b) due to this non-compliance.2. The appellant argued that the retrospective amendment to Rule 6(3) by Finance Act, 2010 allowed manufacturers to reverse proportionate credit even without separate accounts. The appellant had foregone credit for exempted final products, and thus, Rule 6(3)(b) should not apply. The Commissioner's order was challenged on this basis.3. The Tribunal noted the retrospective applicability of the amended Rule 6(3) and cited a relevant judgment supporting the appellant's position. The appellant's compliance with the rule by foregoing credit for exempted products was considered sufficient, rendering the demand under Rule 6(3)(b) invalid. The Tribunal set aside the Commissioner's order and allowed the appeal in favor of the appellant.